Medtronic (NYSE: MDT) reported Q4 EPS of $1.46, $0.01 better than the analyst estimate of $1.45. Revenue for the quarter came in at $8.59 billion versus the consensus estimate of $8.44 billion.

GUIDANCE:

The company is guiding to FY25 organic revenue growth in the range of 4% to 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth on a reported basis would be in the range of 2.4% to 3.7%.

Medtronic sees FY2025 EPS of $5.40-$5.50, versus the consensus of $5.45.

For earnings history and earnings-related data on Medtronic (MDT) click here.

Earnings Guidance

RBC Capital Reiterates Sector Perform Rating on Medtronic, Inc. (MDT)May 24, 2024 6:16 AM Medtronic, Inc. (MDT) PT Raised to $105 at Wells FargoMay 24, 2024 5:20 AM Medtronic, Inc. (MDT) PT Raised to $76 at UBSMay 24, 2024 4:59 AM Stifel Reiterates Buy Rating on Medtronic, Inc. (MDT)May 23, 2024 4:25 PM BTIG Reiterates Neutral Rating on Medtronic, Inc. (MDT)May 23, 2024 4:15 PM